David A. Hollander's most recent trade in Kiora Pharmaceuticals Inc was a trade of 20,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharma Inc | David A. Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Revance Therapeutics Inc | David A. Hollander | CMO & Global Therapeutics Lead | Sale of securities on an exchange or to another person at price $ 4.17 per share. | 18 Nov 2024 | 3,908 | 104,945 (0%) | 0% | 4.2 | 16,296 | Common Stock |
| Kiora Pharma Inc | David A. Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) |